ArticleActa neurochirurgica2026
Next-generation sequencing (NGS) analysis and age-based survival comparison among glioblastoma (GBM) patients: a two-center cohort study.
Article in Acta neurochirurgica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveGlioblastoma (GBM) incidence increases with age, and its etiologies may differ between young and elderly patients. This study aimed to investigate genetic differences between young and elderly GBM patients using next-generation sequencing (NGS) data.
methodsWe retrospectively analyzed 124 GBM patients (< 65 years, n = 60; ≥ 65 years, n = 64) who underwent surgery at two institutions between 2017 and 2022. Clinical and NGS molecular data were analyzed, and survival analysis used the Kaplan-Meier method and Cox regression models.
resultsThe elderly group (≥ 65 years) had a significantly lower OS of 11.0 months compared to 18.0 months in the younger group (p = 0.001). The Stupp protocol, a known prognostic factor, was more frequent in the younger group (p = 0.023). Molecular analysis showed that MGMT methylation was more prevalent in elderly patients than in younger patients (p = 0.009). NGS genetic results showed that ATRX mutations were more common in younger patients than in elderly patients (p = 0.052, Fisher's exact test) but this was not statistically significant. Trends toward higher MET and CDK6 amplification rates were observed in the elderly group compared to the younger group (p = 0.058, Fisher's exact test), although these did not reach statistical significance. Multivariate analysis confirmed that advanced age (HR = 1.961, p = 0.002), MGMT methylation (HR = 0.513, p = 0.004), the Stupp protocol (HR = 0.376, p < 0.001), and GTR (HR = 0.519, p = 0.002) were independent prognostic factors.
conclusionMGMT methylation was significantly more prevalent in elderly GBM patients and favorably influenced prognosis. No NGS-derived genetic alterations reached statistical significance between age groups after Fisher's exact test and multiple testing correction. Larger multicenter studies are needed to validate these exploratory findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.